Immunity to Tumour Antigens

Author(s): G. Li, S. A. Ali, S. E.B. McArdle, S. Mian, M. Ahmad, A. Miles, R. C. Rees

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 27 , 2005


Become EABM
Become Reviewer
Call for Editor

Abstract:

During the last decade, a large number of human tumour antigens have been identified. These antigens are classified as tumour-specific shared antigens, tissue-specific differentiation antigens, overexpressed antigens, tumour antigens resulting from mutations, viral antigens and fusion proteins. Antigens recognised by effectors of immune system are potential targets for antigen-specific cancer immunotherapy. However, most tumour antigens are self-proteins and are generally of low immunogenicity and the immune response elicited towards these tumour antigens is not always effective. Strategies to induce and enhance the tumour antigen-specific response are needed. This review will summarise the approaches to discovery of tumour antigens, the current status of tumour antigens, and their potential application to cancer treatment.

Keywords: tumour antigen, immunotherapy, antigen discovery, tolerance

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 27
Year: 2005
Published on: 01 March, 2012
Page: [3501 - 3509]
Pages: 9
DOI: 10.2174/138161205774414583
Price: $65

Article Metrics

PDF: 3